| Medical and Health Sciences | Lifetime | 831 | FR 17 | 99.96 |
| Medical and Health Sciences | 2021-2025 | 186 | FR 4 | 99.96 |
| Pulmonary and Respiratory Medicine | Lifetime | 57 | FR 5 | 99.93 |
| Medical Physiology | Lifetime | 407 | FR 6 | 99.34 |
| Rheumatology | Lifetime | 414 | FR 18 | 98.23 |
| Pathology and Forensic Medicine | Lifetime | 630 | FR 22 | 97.17 |
| Medical Genetics | Lifetime | 535 | FR 27 | 94.81 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 14 | FR 2 | 99.93 |
| Medical Physiology | 2021-2025 | 46 | FR 2 | 99.36 |
| Pathology and Forensic Medicine | 2021-2025 | 218 | FR 10 | 93.77 |
| Rheumatology | 2021-2025 | 275 | FR 14 | 90.95 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | Lifetime | 13 | FR 1 | 99.86 |
| Sarcoidosis and Beryllium Toxicity Research | Lifetime | 5 | FR 2 | 99.82 |
| Medical Imaging and Pathology Studies | Lifetime | 18 | FR 1 | 99.81 |
| Pulmonary Hypertension Research and Treatments | Lifetime | 23 | FR 5 | 99.74 |
| Eosinophilic Disorders and Syndromes | Lifetime | 23 | FR 2 | 99.69 |
| Systemic Sclerosis and Related Diseases | Lifetime | 35 | FR 6 | 99.57 |
| Vascular Anomalies and Treatments | Lifetime | 14 | FR 5 | 99.42 |
| Chronic Obstructive Pulmonary Disease (COPD) Research | Lifetime | 176 | FR 3 | 99.25 |
| Occupational and environmental lung diseases | Lifetime | 58 | FR 3 | 99.07 |
| Tuberous Sclerosis Complex Research | Lifetime | 30 | FR 2 | 98.24 |
| Vasculitis and related conditions | Lifetime | 118 | FR 13 | 98.39 |
| Inflammatory Myopathies and Dermatomyositis | Lifetime | 91 | FR 7 | 98.58 |
| Tracheal and airway disorders | Lifetime | 548 | FR 30 | 98.18 |
| Occupational exposure and asthma | Lifetime | 129 | FR 1 | 97.56 |
| Pleural and Pulmonary Diseases | Lifetime | 322 | FR 19 | 97.37 |
| Inhalation and Respiratory Drug Delivery | Lifetime | 384 | FR 10 | 97.15 |
| Eosinophilic Esophagitis | Lifetime | 612 | FR 26 | 97.15 |
| Cardiovascular Issues in Pregnancy | Lifetime | 576 | FR 24 | 95.86 |
| Histiocytic Disorders and Treatments | Lifetime | 525 | FR 47 | 88.83 |
| Sharing Economy and Platforms | Lifetime | 630 | FR 13 | 85.71 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 901 | FR 35 | 80.41 |
| Pneumothorax, Barotrauma, Emphysema | Lifetime | 851 | FR 28 | 67.60 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | 2021-2025 | 1 | FR 1 | 99.92 |
| Medical Imaging and Pathology Studies | 2021-2025 | 1 | FR 1 | 99.84 |
| Sarcoidosis and Beryllium Toxicity Research | 2021-2025 | 1 | FR 1 | 99.90 |
| Occupational and environmental lung diseases | 2021-2025 | 1 | FR 1 | 99.43 |
| Occupational exposure and asthma | 2021-2025 | 3 | FR 1 | 98.05 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 15 | FR 2 | 98.97 |
| Pulmonary Hypertension Research and Treatments | 2021-2025 | 28 | FR 6 | 99.01 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 18 | FR 1 | 99.15 |
| Chronic Obstructive Pulmonary Disease (COPD) Research | 2021-2025 | 112 | FR 3 | 98.19 |
| Tuberous Sclerosis Complex Research | 2021-2025 | 26 | FR 2 | 92.61 |
| Inflammatory Myopathies and Dermatomyositis | 2021-2025 | 123 | FR 9 | 93.81 |
| Eosinophilic Esophagitis | 2021-2025 | 293 | FR 6 | 93.51 |
| Inhalation and Respiratory Drug Delivery | 2021-2025 | 354 | FR 7 | 86.88 |
| Transplantation: Methods and Outcomes | 2021-2025 | 909 | FR 44 | 86.46 |
| Vascular Anomalies and Treatments | 2021-2025 | 127 | FR 25 | 82.75 |
| Respiratory and Cough-Related Research | 2021-2025 | 546 | FR 10 | 83.47 |
| Voice and Speech Disorders | 2021-2025 | 675 | FR 8 | 78.58 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 940 | FR 45 | 76.76 |
| Vasculitis and related conditions | 2021-2025 | 830 | FR 80 | 78.57 |
| Polyomavirus and related diseases | 2021-2025 | 751 | FR 48 | 74.53 |
| Phosphodiesterase function and regulation | 2021-2025 | 384 | FR 12 | 44.97 |
| Histiocytic Disorders and Treatments | 2021-2025 | 915 | FR 97 | 25.77 |
